Actively Recruiting

Phase Not Applicable
Age: 12Years +
All Genders
NCT05494346

Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO"

Led by Laboratoires Gilbert · Updated on 2025-09-25

101

Participants Needed

5

Research Sites

157 weeks

Total Duration

On this page

Sponsors

L

Laboratoires Gilbert

Lead Sponsor

E

EVAMED

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by Gilbert Laboratories. The study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.

CONDITIONS

Official Title

Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO"

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient 12 years or older.
  • Patient has acute rhinitis with nasal obstruction during infectious episodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectious episodes such as allergic rhinitis.
  • Informed adult patient with written consent, or informed minor patient with assent and guardian consent before any study procedure.
  • Patient able to follow study requirements for monitoring, spray use, and questionnaire completion.
  • Patient affiliated with a social security scheme.
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding women.
  • Hypersensitivity to seawater or allergies to any spray ingredients.
  • Diseases causing airway narrowing (e.g., asthma, COPD) or respiratory insufficiency.
  • Patients with uncontrolled asthma (GINA score ≥ 4).
  • Patients undergoing allergy desensitization.
  • Chronic nasal obstruction from nasal wall deformation or nasal polyps.
  • Use of local or systemic vasoconstrictors, corticosteroids, NSAIDs, antibiotics, or local antiseptics.
  • Use of other nasal sprays, essential oils, creams, or gels for the nose.
  • Patients under guardianship, conservatorship, or legal protection.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Cabinet Médical

Blainville-sur-Orne, France, 14550

Actively Recruiting

2

Cabinet Médical Caen

Caen, France, 14000

Actively Recruiting

3

MSP du Haut Anjou

Châteauneuf-sur-Sarthe, France, 49330

Actively Recruiting

4

Cabinet Médical Gainneville

Gainneville, France, 76700

Withdrawn

5

ALYATEC

Strasbourg, France, 67000

Completed

Loading map...

Research Team

C

Carine BRUNEL

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO" | DecenTrialz